DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DexCom, Inc. (DXCM) Average EV/Sales Ratio

EV/Sales Ratio

The current ev/sales ratio for DexCom, Inc. (DXCM) is 6.44x as of Tuesday, June 9, 2026, shown against its trailing averages.

Average EV/Sales Ratio Chart

DXCM EV/Sales Ratio Averages

EV/SALES RATIO CURRENT

6.44x

EV/SALES RATIO TTM

6.65x

EV/SALES RATIO 3Y

10.24x

EV/SALES RATIO 5Y

13.90x

EV/SALES RATIO 10Y

13.96x

EV/SALES RATIO 15Y

14.20x

EV/SALES RATIO 20Y

152.64x

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach